Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17373385 | 0.87 | CTSS (0.53) | CTSSCTSKITGB3ITGA2BAAK1 | |
| SCHEMBL20395448 | 0.87 | CTSS (0.53) | CTSSCTSKITGB3ITGA2BAAK1 | |
| SCHEMBL13260654 | 0.84 | CACNA1B (0.52) | CACNA1BITGB3ITGA2BMAPK1 | |
| SCHEMBL375850 | 0.84 | CTSS (0.46) | CTSSCTSKCACNA1BITGB3ITGA2B | |
| SCHEMBL375849 | 0.84 | CTSS (0.46) | CTSSCTSKCACNA1BITGB3ITGA2B | |
| SCHEMBL192265 | 0.84 | CTSK (0.52) | CTSSCTSKCACNA1BHDAC4HDAC1 | |
| SCHEMBL192266 | 0.84 | CTSK (0.52) | CTSSCTSKCACNA1BHDAC4HDAC1 | |
| SCHEMBL375818 | 0.83 | CTSK (0.51) | CTSSCTSKCACNA1BHDAC4HDAC1 | |
| SCHEMBL375819 | 0.83 | CTSK (0.51) | CTSSCTSKCACNA1BHDAC4HDAC1 | |
| SCHEMBL6689450 | 0.79 | CTSS (0.54) | CTSSCTSKAAK1MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | PLK2, PLK4, PLK3 | CTSS 2866/4885CTSK 983/4885CACNA1B 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.